Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,300 peer-reviewed publications.

The CPRD bibliography is updated on a monthly basis (last updated 4 November 2019) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

(PDF, 3MB, 192 pages)

 

Export 121 results:
[ Author(Asc)] Title Type Year
Filters: First Letter Of Last Name is W  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
W
K. M. Wyatt, Dimmock, P. W., Frischer, M., Jones, P. W., and O'Brien, S. P., “Prescribing patterns in premenstrual syndrome”, BMC Womens Health, vol. 2, p. 4, 2002.
K. E. Wurst, Punekar, Y. S., and Shukla, A., “Treatment evolution after COPD diagnosis in the UK primary care setting”, PLoS One, vol. 9, p. e105296, 2014.
K. E. Wurst, Shukla, A., Muellerova, H., and Davis, K. J., “Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study”, Copd, vol. 11, pp. 521-30, 2014.
K. E. Wurst, Ephross, S. A., Loehr, J., Clark, D. W., and Guess, H. A., “Evaluation of the General Practice Research Database congenital heart defects prevalence: comparison to United Kingdom national systems”, Birth Defects Res A Clin Mol Teratol, vol. 79, pp. 309-16, 2007.
K. E. Wurst, Ephross, S. A., Loehr, J., Clark, D. W., and Guess, H. A., “The utility of the general practice research database to examine selected congenital heart defects: a validation study”, Pharmacoepidemiol Drug Saf, vol. 16, pp. 867-77, 2007.
J. W. Wu, Azoulay, L., Majdan, A., Boivin, J. F., Pollak, M., and Suissa, S., “Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes”, J Clin Oncol, vol. 35, pp. 3647-3653, 2017.
T. Wrigley, Tinto, A., and Majeed, A., “Age and sex specific antibiotic prescribing patterns in general practice in England and Wales, 1994 to 1998.”, Health Stat Q, vol. 14, pp. 14-20, 2002.
E. Wright, Schofield, P. T., Seed, P., and Molokhia, M., “Bisphosphonates and risk of upper gastrointestinal cancer–a case control study using the General Practice Research Database (GPRD)”, PLoS One, vol. 7, p. e47616, 2012.
A. K. Wright, Kontopantelis, E., Emsley, R., Buchan, I., Sattar, N., Rutter, M. K., and Ashcroft, D. M., “Life Expectancy and Cause-Specific Mortality in Type 2 Diabetes: A Population-Based Cohort Study Quantifying Relationships in Ethnic Subgroups”, Diabetes Care, vol. 40, pp. 338-345, 2017.
A. K. Wright, Kontopantelis, E., Emsley, R., Buchan, I. E., Mamas, M. A., Sattar, N., Ashcroft, D. M., and Rutter, M. K., “Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes: A Population-Based Cohort Study Assessing Sex Disparities”, Circulation, 2019.
S. Wood, Marchant, A., Allsopp, M., Wilkinson, K., Bethel, J., Jones, H., and John, A., “Epidemiology of eating disorders in primary care in children and young people: a Clinical Practice Research Datalink study in England”, BMJ Open, vol. 9, p. e026691, 2019.
S. L. Wood, Jick, H., and Sauve, R., “The risk of stillbirth in pregnancies before and after the onset of diabetes”, Diabet Med, vol. 20, pp. 703-7, 2003.
I. C. Wong, Asherson, P., Bilbow, A., Clifford, S., Coghill, D., DeSoysa, R., Hollis, C., McCarthy, S., Murray, M., Planner, C., Potts, L., Sayal, K., and Taylor, E., “Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)–a pharmacoepidemiological and qualitative study”, Health Technol Assess, vol. 13, pp. iii-iv, ix-xi, 1-120, 2009.
J. Wong, Donegan, K., Seabroke, S., and Bryan, P., “Evaluation of compliance to the timing of childhood vaccinations following introduction of the meningococcal B vaccine in the UK”, Drug Safety, vol. 40, pp. 1000-1, 2017.
D. B. Wolfson, Best, A. F., Addona, V., Wolfson, J., and Gadalla, S. M., “Benefits of combining prevalent and incident cohorts: An application to myotonic dystrophy”, Stat Methods Med Res, p. 962280218804275, 2018.
A. Wolf, Dedman, D., Campbell, J., Booth, H., Lunn, D., Chapman, J., and Myles, P., “Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum”, Int J Epidemiol, 2019.
K. Wing, Williamson, E., Carpenter, J. R., Wise, L., Schneeweiss, S., Smeeth, L., Quint, J. K., and Douglas, I., “Real-world effects of medications for chronic obstructive pulmonary disease: protocol for a UK population-based non-interventional cohort study with validation against randomised trial results”, BMJ Open, vol. 8, p. e019475, 2018.
K. Wing, Douglas, I., Bhaskaran, K., Klungel, O. H., Reynolds, R. F., Pirmohamed, M., Smeeth, L., and van Staa, T. P., “Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records”, Drug Discov Today, vol. 19, pp. 361-6, 2014.
K. Wing, Bhaskaran, K., Pealing, L., Root, A., Smeeth, L., van Staa, T. P., Klungel, O. H., Reynolds, R. F., and Douglas, I., “Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study”, J Antimicrob Chemother, vol. 72, pp. 2636-2646, 2017.
K. Wing, Bhaskaran, K., Smeeth, L., van Staa, T. P., Klungel, O. H., Reynolds, R. F., and Douglas, I., “Optimising case detection within UK electronic health records: use of multiple linked databases for detecting liver injury”, BMJ Open, vol. 6, p. e012102, 2016.
C. Windsor, Herrett, E., Smeeth, L., and Quint, J. K., “No association between exacerbation frequency and stroke in patients with COPD”, Int J Chron Obstruct Pulmon Dis, vol. 11, pp. 217-25, 2016.
K. Windfuhr, While, D., Kapur, N., Ashcroft, D. M., Kontopantelis, E., Carr, M. J., Shaw, J., Appleby, L., and Webb, R. T., “Suicide risk linked with clinical consultation frequency, psychiatric diagnoses and psychotropic medication prescribing in a national study of primary-care patients”, Psychol Med, vol. 46, pp. 3407-3417, 2016.
C. C. Winchester, Macfarlane, T. V., Thomas, M., and Price, D., “Antibiotic prescribing and outcomes of lower respiratory tract infection in UK primary care”, Chest, vol. 135, pp. 1163-1172, 2009.
I. Wilting, de Vries, F., Thio, B. M., Cooper, C., Heerdink, E. R., Leufkens, H. G., Nolen, W. A., Egberts, A. C., and van Staa, T. P., “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
C. L. Wilson, Rhodes, K. M., and Payne, R. A., “Financial incentives improve recognition but not treatment of cardiovascular risk factors in severe mental illness”, PLoS One, vol. 12, p. e0179392, 2017.
J. C. Wilson, Toovey, S., Jick, S. S., and Meier, C. R., “Previously diagnosed influenza infections and the risk of developing epilepsy”, Epidemiol Infect, vol. 143, pp. 2408-15, 2015.
J. C. Wilson, Sarsour, K., Gale, S., Petho-Schramm, A., Jick, S. S., and Meier, C. R., “Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis”, Arthritis Care Res (Hoboken), 2018.
J. C. Wilson, Sarsour, K., Collinson, N., Tuckwell, K., Musselman, D., Klearman, M., Napalkov, P., Jick, S. S., Stone, J. H., and Meier, C. R., “Incidence of outcomes potentially associated with corticosteroid therapy in patients with giant cell arteritis”, Semin Arthritis Rheum, vol. 46, pp. 650-656, 2017.
J. C. Wilson, Sarsour, K., Collinson, N., Tuckwell, K., Musselman, D., Klearman, M., Napalkov, P., Jick, S. S., Stone, J. H., and Meier, C. R., “Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis”, Semin Arthritis Rheum, vol. 46, pp. 819-827, 2017.
J. C. Wilson, Furlano, R. I., Jick, S. S., and Meier, C. R., “Inflammatory Bowel Disease and the Risk of Autoimmune Diseases”, J Crohns Colitis, vol. 10, pp. 186-93, 2016.
J. C. Wilson, Furlano, R. I., Jick, S. S., and Meier, C. R., “A population-based study examining the risk of malignancy in patients diagnosed with inflammatory bowel disease”, J Gastroenterol, vol. 51, pp. 1050-1062, 2016.
J. C. Wilson, O'Rorke, M. A., Cooper, J. A., Murray, L. J., Hughes, C. M., Gormley, G. J., and Anderson, L. A., “Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the Clinical Practice Research Datalink”, Cancer Epidemiol, vol. 37, pp. 897-904, 2013.
A. B. Wilson, Neogi, T., Prout, M., and Jick, S., “Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database”, Cancer Epidemiol, vol. 38, pp. 544-9, 2014.
E. Williamson, Denaxas, S., Morris, S., Clarke, C. S., Thomas, M., Evans, H., Direk, K., Gonzalez-Izquierdo, A., Little, P., Lund, V., Blackshaw, H., Schilder, A., Philpott, C., Hopkins, C., and Carpenter, J., “Risk of mortality and cardiovascular events following macrolide prescription in chronic rhinosinusitis patients: a cohort study using linked primary care electronic health records”, Rhinology, 2019.
I. Williamson, Benge, S., Mullee, M., and Little, P., “Consultations for middle ear disease, antibiotic prescribing and risk factors for reattendance: a case-linked cohort study”, Br J Gen Pract, vol. 56, pp. 170-5, 2006.
R. Williams, van Staa, T. P., Gallagher, A. M., Hammad, T., Leufkens, H. G. M., and de Vries, F., “Cancer recording in patients with and without type 2 diabetes in the Clinical Practice Research Datalink primary care data and linked hospital admission data: a cohort study”, BMJ Open, vol. 8, p. e020827, 2018.
R. Williams, de Vries, F., Kothny, W., Serban, C., Lopez-Leon, S., Chu, C., and Schlienger, R., “Cardiovascular safety of vildagliptin in patients with type 2 diabetes: A European multi-database, non-interventional post-authorization safety study”, Diabetes Obes Metab, vol. 19, pp. 1473-1478, 2017.
R. Williams, Kothny, W., Serban, C., Lopez-Leon, S., and Schlienger, R., “Pancreatic safety of vildagliptin in patients with type 2 diabetes mellitus: A European, noninterventional, postauthorization safety study”, Endocrinol Diabetes Metab, vol. 2, p. e00052, 2019.
R. Williams, Kothny, W., Serban, C., Lopez-Leon, S., de Vries, F., and Schlienger, R., “Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study”, Endocrinol Diabetes Metab, vol. 2, p. e00084, 2019.
M. J. Willemen, Mantel-Teeuwisse, A. K., Straus, S. M., Leufkens, H. G., and Egberts, A. C., “Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs”, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
C. Willame, Baril, L., van den Bosch, J., Ferreira, G. L., Williams, R., Rosillon, D., and Cohet, C., “Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies”, Pharmacoepidemiol Drug Saf, vol. 25, pp. 1397-1406, 2016.
C. Willame, Rosillon, D., Zima, J., Angelo, M. G., Stuurman, A. L., Vroling, H., Boggon, R., Bunge, E. M., Pladevall-Vila, M., and Baril, L., “Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom”, Hum Vaccin Immunother, vol. 12, pp. 2862-2871, 2016.
S. Wilkinson, Douglas, I., Stirnadel-Farrant, H., Fogarty, D., Pokrajac, A., Smeeth, L., and Tomlinson, L., “Changing use of antidiabetic drugs in the UK: trends in prescribing 2000-2017”, BMJ Open, vol. 8, p. e022768, 2018.
T. Wilke, Mueller, S., Groth, A., Berg, B., Fuchs, A., Sikirica, M., Logie, J., Martin, A., and Maywald, U., “Non-Persistence and Non-Adherence of Patients with Type 2 Diabetes Mellitus in Therapy with GLP-1 Receptor Agonists: A Retrospective Analysis”, Diabetes Ther, vol. 7, pp. 105-24, 2016.
J. P. H. Wilding, Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., Clauson, P., Fenici, P., Hammar, N., and Medina, J., “Changes in HbA1c and weight after initiation of second-line therapy in patients with type 2 diabetes in clinical practice.”, Diabetologia., vol. 60, p. S301, 2017.
J. Wilding, Bailey, C., Rigney, U., Blak, B., Kok, M., and Emmas, C., “Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up”, Prim Care Diabetes, vol. 11, pp. 437-444, 2017.
J. Wilding, Bailey, C., Rigney, U., Blak, B., Beekman, W., and Emmas, C., “Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study”, Diabetes Ther, vol. 7, pp. 695-711, 2016.
J. Wilding, Godec, T., Khunti, K., Pocock, S., Fox, R., Smeeth, L., Clauson, P., Fenici, P., Hammar, N., and Medina, J., “Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink”, BMC Med, vol. 16, p. 116, 2018.
R. N. Wild, “Micturin and torsades de pointe — experience of a post‐marketing alert”, vol. 1, pp. 147 - 150, 1992.
J. M. Wijnands, van Durme, C. M., Driessen, J. H., Boonen, A., Klop, C., Leufkens, B., Cooper, C., Stehouwer, C. D., and de Vries, F., “Individuals With Type 2 Diabetes Mellitus Are at an Increased Risk of Gout But This Is Not Due to Diabetes: A Population-Based Cohort Study”, Medicine (Baltimore), vol. 94, p. e1358, 2015.
[Page last reviewed 4 November 2019]